Tharimmune (THAR) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
2 Feb, 2026Opening remarks and agenda
Meeting called to order by CEO Mark Wendland, with CFO Jacob Asbury as Secretary and Francis H. Bird as Inspector of Election.
Meeting conducted in listen-only mode, with Q&A available after proposals.
Quorum confirmed, allowing lawful conduct of business as per notice and proxy statement.
Specific resolutions to be voted on
Election of two directors: Jill E. Summers and William Wiley, for terms expiring at the next annual meeting.
Approval of issuance of shares upon exercise of Strategic Advisor Warrants to strategic investors.
Approval of issuance of shares upon exercise of Cryptocurrency Pre-Funded Warrants from the November 3, 2025 private placement.
Approval of issuance of restricted stock units to Clear Street, LLC, and shares upon settlement, related to the November 3, 2025 private placement.
Approval of amendment to the 2023 Omnibus Equity Incentive Plan to increase available shares by 7 million.
Approval of potential adjournment of the meeting to solicit further votes if needed.
Overview of voting outcomes
All proposals, including director elections, warrant and stock issuances, equity plan amendment, and adjournment, were approved by majority vote.
Adjournment was not necessary as all main proposals passed.
Latest events from Tharimmune
- Board nominees are confirmed as independent; voting process for the special meeting is unchanged.THAR
Proxy Filing27 Jan 2026 - Shareholders to vote on director elections, equity issuances, and plan amendments at virtual meeting.THAR
Proxy Filing16 Jan 2026 - $2B shelf registration supports blockchain and biotech growth, following a $545M PIPE raise.THAR
Registration Filing9 Jan 2026 - Shareholders to vote on board expansion, equity issuances, and a 7M-share plan increase.THAR
Proxy Filing6 Jan 2026 - Shareholders to vote on new directors, warrant issuances, and a 7M-share equity plan increase.THAR
Proxy Filing16 Dec 2025 - Raised $545M for a digital asset treasury strategy; offering is secondary, no new capital raised.THAR
Registration Filing16 Dec 2025 - Biotech registers 1.44M shares for resale from $2.02M private placement, funding R&D.THAR
Registration Filing16 Dec 2025 - Biotech registers 1M+ shares for resale after $2.08M private placement, funding R&D amid risks.THAR
Registration Filing16 Dec 2025 - Registering 4.2M shares for resale, with proceeds from warrants funding R&D amid Nasdaq compliance risk.THAR
Registration Filing16 Dec 2025